External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

ISTH 2022

July 09 - July 13

London, UK / Virtual (Hybrid)

isth2022.org

Add to calendar

Medical Materials

Agenda

Coming soon

11:45 AM

Duration 15mins ExCel Center, ICC Auditorium

Emicizumab▼ Prophylaxis for the Treatment of People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 6 Study

Hermans C, Negrier C, Lehle M, Chowdary P, Catalani O, Jiménez-Yuste V, Beckermann BM, Schmitt C, Ventriglia G, Windyga J, Kiialainen A, d’Oiron R, Moorehead P, Koparkar S, Teodoro V, Shapiro AD, Oldenburg J

Haematology | Hemophilia A

Add to calendar

03:30 PM

Duration 15mins ExCel Center, ICC Auditorium

Safety and Efficacy of Emicizumab▼ in People with Hemophilia A Enrolled in the Hemophilia Natural History Study (ATHN 7)

Buckner TW, Carpenter SL, Kempton CL, Lee L, Malec L, McLean TW, Morton P, Staber JM, Wang M, Recht M

Haematology | Hemophilia A

Add to calendar

Duration 5mins London, UK / Virtual (Hybrid)

Infographic Summary of Safety and Efficacy of Emicizumab▼ in People with Hemophilia A Enrolled in the Hemophilia Natural History Study (ATHN 7)

Buckner TW, Recht M et al

Haematology | Hemophilia A

Add to calendar

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.